Array
(
)
1
> Pathway Inhibitors>Enzyme Inhibitors>Kinase Inhibitors>RIm13

Kinase Inhibitors

RIm13 View larger

RIm13

AOB13411

CAS: 2375075-75-3

 

Chemical Name: 5-(3'-Benzyl-5-(4-methoxyphenyl)-1-methyl-1H,3'H,3''H-[2,4':2',4''-terimidazol]-3''-yl)-N-methylpentan-1-amine

More details

2000 Items

Molarity Calculation Cart®

HOW TO ORDER

$49.00

$49.00 per 0.5 mL

Quantity Discount Table - Order More To Get More Price Discount

Quantity (mg or Unit)Unit Price ($/mg or $/Unit)Final Price
5 $41.65 Total: $208.25
10 $35.28 Total: $352.80
25 $29.89 Total: $747.25
50 $25.48 Total: $1,274.00
100 $22.05 Total: $2,205.00

Data sheet

Molecular FormulaC30H35N7O
Molecular Weight509.66
CAS Numbers2375075-75-3
Storage Condition0°C (short term), -20°C (long term), desiccated
SolubilityDMSO and Alcohol
Purity98% by HPLC
IUPAC/Chemical Name5-(3'-Benzyl-5-(4-methoxyphenyl)-1-methyl-1H,3'H,3''H-[2,4':2',4''-terimidazol]-3''-yl)-N-methylpentan-1-amine
SMILES CodeCXHJQCQAKUNWMJ-UHFFFAOYSA-N

More info

Novel potent inhibitor of Proprotein convertase subtilisin/kexin 9 (PCSK9), targeting the PCSK9/LDLR protein-protein interaction

Mechanism of action

  • RIm13 is described as a small-molecule drug whose main therapeutic target is the enzyme/protein PCSK9 (proprotein convertase subtilisin/kexin type 9). Synapse+1

  • By inhibiting PCSK9, the compound aims to reduce the levels of low-density lipoprotein cholesterol (LDL-C). The rationale: PCSK9 normally binds to LDL receptors on liver cells and leads to their degradation, thus fewer LDL receptors means less clearance of LDL-C from the bloodstream. Inhibiting PCSK9 therefore increases LDL receptor availability and promotes LDL-C clearance. DOAJ+1

Development status & functional implications

  • RIm13 is currently in the pre-clinical stage (i.e., not yet in approved clinical use). Synapse+1

  • Its intended therapeutic indication is for hypercholesterolemia (elevated LDL cholesterol) via PCSK9 inhibition. Synapse

  • Because it is still in early development, detailed functional data in humans (pharmacodynamics, pharmacokinetics, safety profile) are not publicly available.

  • The general functionality (from the class of PCSK9 inhibitors) suggests that if successful, RIm13 might:

    • Lower LDL-C levels significantly (based on what is known from PCSK9 inhibitors generally).

    • Potentially reduce risk of cardiovascular events associated with high LDL-C (though this depends on clinical outcomes).